Vima Therapeutics Secures $40 Million to Advance Dystonia Treatment into Parkinson’s Research
Vima Therapeutics, a US-based biotechnology firm, has successfully raised $40 million in a Series A extension, enhancing its total funding for this round to $100 million. This financing initiative was…